Andrew Kambugu
Born
Andrew Ddungu Kambugu

1973 (age 50–51)
Uganda
NationalityUgandan
Alma materMakerere University
(Bachelor of Medicine and Surgery),
(Master of Public Health),
Royal College of Physicians
(Post Doctoral Fellowship)
Occupation(s)Physician researcher and academic
Years active1998—present
TitleThe Sande-McKinnell Executive Director at Infectious Disease Institute
SpouseJoyce Balagadde-Kambugu

Andrew Ddungu Kambugu is a Ugandan physician who serves as The Sande-McKinnell Executive Director at Uganda Infectious Disease Institute[1] and a Honorary Senior lecturer at Makerere University College of Sciences.[2] He is also an Adjunct Associate Professor at the University of Minnesota.[3][2] In July 2020, he was appointed to the United Nations 2021 Food System Scientific Group.[4][5][6]

Early life and education

Kambugu was born on 22 February 1973 in Kampala, Uganda. He attended Buganda Road Primary School, King's College Budo for both O & A level and in 1992 he was enrolled at Makerere University, Uganda for a Bachelor of Medicine and surgery and a Masters degree in Medicine specialising in Internal Medicine graduating in 1997 and 2002 respectively.[1] He is a trained fellow in infectious diseases from University of Manitoba.[6][2]

Career

Kambugu did his medical internship at Mulago National hospital in Kampala (1997–98) and has served as a Medical Officer of Uganda Telecom (1998-1999), as a Medical Resident in the Department of Medicine at Makerere University Medical School (October 1998-November 2002),[7] as a physician attending Ward 4B at Mulago Hospital (December 2002 - August 2005) as Head of Preventative Care and Treatment Programme (2005-2012),[7] as Head of Research Programme (May 2012- update) and in May 2013 he was appointed as The Sande-McKinnell Executive Director at Infectious Disease Institute.[6][1] Kambugu is a Honorary Senior lecturer in the Department of Medicine at Makerere University College of Health Sciences.[2] He has presented at Medical conferences inside and outside Uganda such as at Retroviruses and Opportunistic Infections, The International AIDS conference, The South Africa HIV Clinicians Society (2014, 2016), The International Workshop on HIV in Resource Limited Settings(2012, 2014, 2015 $2016).[8] Kambugu serves as a consultant to the World Health Organization on Antiretroviral Therapy since 2010.[9]

Research

He is cited with an H-Index of 39, i10 index of 120 and with 6598 citations in over 120 peer-reviewed journal in scientific publications.[10][11] He is a Council member for African Centers of Excellence in Bioinformatics.[6][12]

Some of his most cited articles are listed below;

  • Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis[13]
  • Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy[14]
  • Retention in care among HIV-infected patients in resource-limited settings: emerging insights and new directions[15]
  • Cost-Effectiveness of Serum Cryptococcal Antigen Screening to Prevent Deaths among HIV-Infected Persons with a CD4+ Cell Count ≤100 Cells/μL Who Start HIV Therapy in Resource-Limited Settings[16]
  • Clinical features and serum biomarkers in HIV immune reconstitution inflammatory syndrome after cryptococcal meningitis: a prospective cohort study[17]
  • Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy
  • Paucity of initial cerebrospinal fluid inflammation in cryptococcal meningitis is associated with subsequent immune reconstitution inflammatory syndrome[18]
  • Assessment of second-line antiretroviral regimens for HIV therapy in Africa[19]
  • Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy[20]
  • Tuberculosis immune reconstitution inflammatory syndrome in countries with limited resources[21]
  • Cause-specific mortality and the contribution of immune reconstitution inflammatory syndrome in the first 3 years after antiretroviral therapy initiation in an urban African cohort[21]
  • Retention in Care and Patient-Reported Reasons for Undocumented Transfer or Stopping Care Among HIV-Infected Patients on Antiretroviral Therapy in Eastern Africa: Application of a Sampling-Based Approach[22]
  • Belief in divine healing can be a barrier to antiretroviral therapy adherence in Uganda[23]

Personal life

Kambugu is married to Joyce Balagadde-Kambugu and they have two children.[24]

References

  1. 1 2 3 "Dr. Andrew D Kambugu". Infectious Diseases Institute. Retrieved 19 December 2020.
  2. 1 2 3 4 "Dr. Andrew D Kambugu, M.Med, FRCP (London)". Health Informatics Research Group. December 7, 2017.
  3. ↑ "PROFILE: Makerere University's Prof. Waiswa appointed on WHO advisory board - Education News Uganda". Archived from the original on 2020-05-17. Retrieved 2020-12-18.
  4. ↑ "Advisory Committee and Scientific Group for the 2021 Food Systems Summit". United Nations Secretary-General. June 29, 2020.
  5. ↑ "The Executive Director, Dr Andrew Kambugu named on the UN 2021 Food Systems Summit « INFECTIOUS DISEASES INSTITUTE".
  6. 1 2 3 4 "Andrew Kambugu « Interest Conference".
  7. 1 2 "Andrew Kambugu – Researchers for Global Health".
  8. ↑ https://edge.ug/2020/07/09/makereres-dr-kambugu-named-on-un-2021-food-systems-summit-scientific-group/
  9. ↑ Wamai, Mark (July 1, 2020). "IDI's Dr. Kambugu Named on UN 2021 Food Systems Summit Scientific Group". Makerere University News.
  10. ↑ "Andrew Kambugu". scholar.google.com. Retrieved 2022-05-23.
  11. ↑ "Andrew Kambugu".
  12. ↑ "Global Council | ACE". ace.niaid.nih.gov.
  13. ↑ Boulware, David R.; Meya, David B.; Muzoora, Conrad; Rolfes, Melissa A.; Huppler Hullsiek, Katherine; Musubire, Abdu; Taseera, Kabanda; Nabeta, Henry W.; Schutz, Charlotte; Williams, Darlisha A.; Rajasingham, Radha (2014-06-26). "Timing of Antiretroviral Therapy after Diagnosis of Cryptococcal Meningitis". New England Journal of Medicine. 370 (26): 2487–2498. doi:10.1056/NEJMoa1312884. ISSN 0028-4793. PMC 4127879. PMID 24963568.
  14. ↑ Kambugu, Andrew; Meya, David B; Rhein, Joshua; O'Brien, Meagan; Janoff, Edward N; Ronald, Allan R; Kamya, Moses R; Mayanja-Kizza, Harriet; Sande, Merle A; Bohjanen, Paul R; Boulware, David R (2008-06-01). "Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy". Clinical Infectious Diseases. 46 (11): 1694–1701. doi:10.1086/587667. ISSN 1537-6591. PMC 2593910. PMID 18433339.
  15. ↑ Geng, Elvin H.; Nash, Denis; Kambugu, Andrew; Zhang, Yao; Braitstein, Paula; Christopoulos, Katerina A.; Muyindike, Winnie; Bwana, Mwebesa Bosco; Yiannoutsos, Constantin T.; Petersen, Maya L.; Martin, Jeffrey N. (2010-11-01). "Retention in Care among HIV-Infected Patients in Resource-Limited Settings: Emerging Insights and New Directions". Current HIV/AIDS Reports. 7 (4): 234–244. doi:10.1007/s11904-010-0061-5. ISSN 1548-3576. PMC 3021803. PMID 20820972.
  16. ↑ "Cost-Effectiveness of Serum Cryptococcal Antigen Screening to Prevent Deaths among HIV-Infected Persons with a CD4+ Cell Count ≤100 Cells/μL Who Start HIV Therapy in Resource-Limited Settings". doi:10.1086/655143. Retrieved 2022-05-26.
  17. ↑ Boulware, David R.; Meya, David B.; Bergemann, Tracy L.; Wiesner, Darin L.; Rhein, Joshua; Musubire, Abdu; Lee, Sarah J.; Kambugu, Andrew; Janoff, Edward N.; Bohjanen, Paul R. (2010-12-21). "Clinical Features and Serum Biomarkers in HIV Immune Reconstitution Inflammatory Syndrome after Cryptococcal Meningitis: A Prospective Cohort Study". PLOS Medicine. 7 (12): e1000384. doi:10.1371/journal.pmed.1000384. ISSN 1549-1676. PMC 3014618. PMID 21253011.
  18. ↑ Boulware, David R.; Bonham, Shulamith C.; Meya, David B.; Wiesner, Darin L.; Park, Gregory S.; Kambugu, Andrew; Janoff, Edward N.; Bohjanen, Paul R. (2010). "Paucity of Initial Cerebrospinal Fluid Inflammation in Cryptococcal Meningitis Is Associated with Subsequent Immune Reconstitution Inflammatory Syndrome". The Journal of Infectious Diseases. 202 (6): 962–970. doi:10.1086/655785. ISSN 0022-1899. JSTOR 20780210. PMC 2924457. PMID 20677939.
  19. ↑ Paton, Nicholas I.; Kityo, Cissy; Hoppe, Anne; Reid, Andrew; Kambugu, Andrew; Lugemwa, Abbas; van Oosterhout, Joep J.; Kiconco, Mary; Siika, Abraham; Mwebaze, Raymond; Abwola, Mary (2014-07-17). "Assessment of Second-Line Antiretroviral Regimens for HIV Therapy in Africa". New England Journal of Medicine. 371 (3): 234–247. doi:10.1056/NEJMoa1311274. ISSN 0028-4793. PMID 25014688. S2CID 2031064.
  20. ↑ Reid, Andrew; Stohr, Wolfgang; Walker, Sarah A.; Williams, Ian G.; Kityo, Cissy; Hughes, Peter; Kambugu, Andrew; Gilks, Charles F.; Mugyenyi, Peter; Munderi, Paula; Hakim, James (2008). "Severe Renal Dysfunction and Risk Factors Associated with Renal Impairment in HIV-Infected Adults in Africa Initiating Antiretroviral Therapy". Clinical Infectious Diseases. 46 (8): 1271–1281. doi:10.1086/533468. PMID 18444867.
  21. 1 2 Castelnuovo, Barbara; Manabe, Yukari C.; Kiragga, Agnes; Kamya, Moses; Easterbrook, Philippa; Kambugu, Andrew (2009). "Cause-Specific Mortality and the Contribution of Immune Reconstitution Inflammatory Syndrome in the First 3 Years after Antiretroviral Therapy Initiation in an Urban African Cohort". Clinical Infectious Diseases. 49 (6): 965–972. doi:10.1086/605500. ISSN 1058-4838. JSTOR 27799241. PMID 19673615. S2CID 19822326.
  22. ↑ "Retention in Care and Patient-Reported Reasons for Undocumented Transfer or Stopping Care Among HIV-Infected Patients on Antiretroviral Therapy in Eastern Africa: Application of a Sampling-Based Approach". doi:10.1093/cid/civ1004. Retrieved 2022-05-26.
  23. ↑ Wanyama, Jane; Castelnuovo, Barbara; Wandera, Bonnie; Mwebaze, Patricia; Kambugu, Andrew; Bangsberg, David R.; Kamya, Moses R. (2007-07-11). "Belief in divine healing can be a barrier to antiretroviral therapy adherence in Uganda". AIDS. 21 (11): 1486–1487. doi:10.1097/QAD.0b013e32823ecf7f. ISSN 0269-9370. PMID 17589198. S2CID 7250684.
  24. ↑ "Dr. Andrew Kambugu « INFECTIOUS DISEASES INSTITUTE".
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.